Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:7
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 3 od 97  
Back povratak na rezultate
2021, vol. 22, br. 3, str. 233-240
Populaciona farmakokinetika vankomicina kod odraslih pacijenata sa prelomima dugih kostiju
aUniverzitet u Kragujevcu, Fakultet medicinskih nauka, Katedra za farmakologiju i toksikologiju
bKlinički centar Kragujevac, Služba za kliničku farmakologiju

e-adresaradica_zivkovic@yahoo.com
Projekat:
Farmakološka analiza efekata biološki aktivnih supstanci na izolovane glatke mišiće gastrointestinalnog i urogenitalnog trakta čoveka (MPNTR - 175007)

Ključne reči: vancomycin; population pharmacokinetics; trauma; non-linear mixed effects model (NONMEM)
Sažetak
Vankomicin je triciklicni glikopeptidni antibiotik, koji se koristi u terapiji teških infekcija izazvanih stafilokokom i enterokokom, posebno u ortopedskoj hirurgiji. Svrha ovog istraživanja bila je da se razvije populacioni farmakokinetski (PPF) model vankomicina kod hospitalizovanih pacijenata sa prelomima dugih kostiju i da se utvrde faktori koji su bitni za klirens (KL) vankomicina. Devedest devet uzoraka seruma sa izmerenim koncentracijama vankomicina je korišćeno za naš model. Model sa dva prostora je korišćen da opiše farmakokinetiku vankomicina sa potprogramima ADVAN3 i TRANS4. Populacija je uključivala oba pola, sa prosečnom starošću 62,12±14,69 godina i telesnom težinom 80,32±12,44 kg. Vankomicin je primenjivan u obliku intravenske infuzije sa prosečnom dnevnom dozom 1772,73±521,34 mg. Analizirano je dvadeset faktora, a utvrđeno je da samo dnevna doza vankomicina i primena piperacilin tazobaktama značajno utiču na klirens vankomicina. Završni model je opisan jednačinom: KL (l/h) = 0.03 + 0.000468 x DD + 0.675 x PT. Butstrap analiza je korišćena za validaciju krajnjeg modela. U zaključku, glavni uzroci varijabilnosti klirensa vankomicina među odraslim pacijentima sa prelomima dugih kostiju jesu dnevna doza vankomicina i komedikacija piperacilin tazobaktamom.
Reference
Novododat članak: provera, normiranje i linkovanje referenci u toku.
Jarkowski A, Forrest A, Sweeney RP et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91-6
Marsot A, Boulamery A, Bruguerolle B et al. Vancomycin: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2012;51(1):1-13
Adane ED, Herald M, Koura F. Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections. Pharmacotherapy. 2015;35(2):127-39
Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;6:848-52
Darko W, Medicis JJ, Smith A et al. Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy. 2003;23(5):643-50
Lodise TP, Patel N, Lomaestro BM et al. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis. 2009;49(4):507-14
De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-94
Purwonugroho TA, Chulavatnatol S, Preechagoon Y et al. Population Pharmacokinetics of Vancomycin in Thai Patients. Scientific World Journal. 2012;2012:762649
Lin WW, Wu W, Jiao Z et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2016;72(1):29-37
Stockmann C, Hersh AL, Roberts JK et al. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther. 2015;4(2):187-98
Hahn A, Frenck RW Jr, Zou Y et al. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit. 2015;37(3):413-6
Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Parts I-VIII ICON Development Solutions
Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokineticpharmacodynamic study: a journal's perspective. Clin Pharmacokinet. 2014;53(2):111-2
Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study.Acta Anaesthesiol Scand. 2017;61(6): 627-35
Campassi ML, Gonzalez MC, Masevicius FD et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment. Rev Bras Ter Intensiva. 2014; 26:13-20
Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49: 325-7
Saugel B, Gramm C, Wagner JY et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014; 29:351-5
Hutschala D, Kinstner C, Skhirdladze K et al. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion. Anesthesiology. 2009;111(2): 356-65
Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136-47
Nakamura T, Hashimoto Y, Kokuryo T et al. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical research.1998;15(5):734-8
Philadelphia, PA: Pfizer; 2012. Zosyn (piperacillin - tazobactam) package insert. https://www.pfizer medicalinformation.com/en-us/zosyn/storagehandling
Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017;64 (5):666-74
Blevins AM, Lashinsky JN, McCammon C et al. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin/Tazobactam, Cefepime, or Merope nem. Antimicrob Agents Chemother. 2019. pii:AAC.02658-18
Kim T, Kandiah S, Patel M et al. Risk factors for kidney injury during vancomycin and piperacillin/ tazobactam administration, including increased odds of injury with combination therapy. BMC research notes. 2015;8(1):579
Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471-9
Sanchez JL, Dominguez AR, Lane JR et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48: 525-33
Garaud JJ, Regnier B, Ingleber F et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14, Suppl. D, 53-5
Rotschafer JC, Crossley K, Zaske DE et al. Pharmacokinetics of Vancomycin: Observations in 28 Patients and Dosage Recommendations. Antimicrob Agents Chemother. 1982;22(3):391-4
Al-Kofide H, Zaghloul I, Al-Naim L Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16(4):245-50
Moore JN, Healy JR, Thoma BN et al. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane. CPT Pharmacometrics Syst Pharmacol. 2016;5(9): 495-502
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2478/sjecr-2019-0025
primljen: 05.04.2019.
prihvaćen: 31.05.2019.
objavljen u SCIndeksu: 26.11.2021.

Povezani članci

Nema povezanih članaka